NCT04539808View on ClinicalTrials.gov

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

April 15, 2025

Study Completion Date

October 5, 2025

Conditions
Pancreatic AdenocarcinomaStage 0 Pancreatic Cancer AJCC v8Stage I Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8
Interventions
DRUG

Capecitabine

Given PO

DRUG

Fluorouracil

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Losartan Potassium

Given PO

DRUG

Oxaliplatin

Given IV

RADIATION

Radiation Therapy

Undergo short-course or long-course RT

PROCEDURE

Resection

Undergo surgical resection

PROCEDURE

Diagnostic Imaging

Undergo diagnostic imaging

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER